Iridex Comments on Recent Stock Price Volatility
Rhea-AI Summary
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has addressed recent stock price volatility observed on March 13, 2025. The company explicitly stated there are no material developments or changes to its operating or financial condition that would explain the recent price and volume movements.
The company confirmed that no material adverse changes have occurred to its operating results, business, strategy, or prospects since their preliminary Q4 and full year 2024 results announcement on January 14, 2025. Final financial results will be discussed during a conference call scheduled for March 27, 2025, at 2:00pm PT.
Positive
- No adverse changes in operating results or business conditions since Q4 2024 preliminary results
Negative
- Unusual stock price volatility and trading volume without fundamental business cause
News Market Reaction 1 Alert
On the day this news was published, IRIX gained 16.49%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today commented on its recent stock price volatility.
The company is not aware of any material developments or changes to its operating or financial condition that precipitated the volume and price movements that occurred on March 13, 2025. There have been no material adverse changes to the company’s operating results, its business, strategy, or prospects since the company provided preliminary operating and financial results for the fourth quarter and full year 2024 on January 14, 2025.
Final fourth quarter and full year 2024 financial results will be released and discussed as previously announced on a conference call scheduled for 2:00pm PT on Thursday, March 27, 2025. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
What caused the stock price volatility in IRIX shares on March 13, 2025?
When will Iridex (IRIX) release its Q4 and full year 2024 financial results?
Has there been any change in Iridex's (IRIX) business strategy since January 2025?
How can investors join Iridex's (IRIX) upcoming earnings call?
